Protagonist Therapeutics (PTGX) Expected to Post Earnings on Tuesday

Protagonist Therapeutics (NASDAQ:PTGX) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $56.65 million for the quarter.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $38.67 on Tuesday. Protagonist Therapeutics has a 1 year low of $24.22 and a 1 year high of $48.89. The firm has a market cap of $2.30 billion, a PE ratio of 14.54 and a beta of 2.22. The company has a 50 day simple moving average of $38.61 and a two-hundred day simple moving average of $41.86.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PTGX shares. JPMorgan Chase & Co. upped their price objective on Protagonist Therapeutics from $51.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. The Goldman Sachs Group initiated coverage on shares of Protagonist Therapeutics in a research note on Friday, December 6th. They issued a “neutral” rating and a $47.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Insider Activity at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the completion of the sale, the chief executive officer now directly owns 435,208 shares in the company, valued at approximately $20,437,367.68. This represents a 15.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suneel Gupta sold 103,437 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $46.04, for a total value of $4,762,239.48. Following the transaction, the insider now owns 256,174 shares in the company, valued at approximately $11,794,250.96. This represents a 28.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 207,957 shares of company stock worth $9,611,739 in the last three months. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.